Equillium, Inc.
Equillium, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Equillium, Inc..
Equillium, Inc. is a company.
Key people at Equillium, Inc..
Equillium, Inc. is a clinical-stage biotechnology company focused on developing novel immunomodulatory therapeutics for severe autoimmune and inflammatory disorders with high unmet medical needs.[1][2][3][4][5] Its pipeline includes lead candidate itolizumab (EQ001), a monoclonal antibody targeting the CD6 immune checkpoint receptor for conditions like acute graft-versus-host disease (Phase 3), alongside multi-cytokine inhibitors such as BNZ-1 for cutaneous T-cell lymphoma (Phase 2) and earlier-stage assets like EQ-102 for celiac disease.[1][2] The company serves patients with immuno-inflammatory diseases, addressing unmet needs through targeted immune pathway modulation, with rights to itolizumab acquired via an exclusive license from Biocon for key markets including the U.S., Canada, Australia, and New Zealand.[1][2]
Founded in 2017 and based in California, Equillium leverages immunobiology expertise to advance its platform, showing clinical momentum through ongoing trials and a growing portfolio of synthetic peptides, cytokines, and antibodies.[2][3]
Equillium was founded in 2017 in California as a biotechnology venture aimed at tackling severe autoimmune and inflammatory disorders.[3] At inception, the company secured exclusive rights to develop and commercialize itolizumab—a first-in-class anti-CD6 monoclonal antibody—through a collaboration and license agreement with Biocon, building on itolizumab's prior approval in India in 2013 for other indications.[1][2] This foundational deal provided early traction, enabling Equillium to advance EQ001 into clinical stages targeting acute graft-versus-host disease and other unmet needs.[2] The team's mission emphasizes pioneering innovations to improve patient lives, supported by an executive team, board, and scientific advisors focused on immunobiology.[1]
Equillium stands out in the biotech landscape through its specialized focus on immunobiology and a pipeline of first-in-class assets:
Equillium rides the wave of precision immunology in biotech, capitalizing on advances in understanding immune checkpoints like CD6 and multi-cytokine signaling to treat complex autoimmune diseases where broad immunosuppressants fall short.[1][2] Timing aligns with rising demand for targeted therapies amid growing autoimmune disorder prevalence—driven by aging populations and environmental factors—and regulatory emphasis on orphan indications like GVHD.[2] Market forces favoring it include biotech funding for inflammatory pipelines and partnerships with originators like Biocon, positioning Equillium to influence the ecosystem by validating novel targets and expanding multi-cytokine platforms into underserved areas like celiac and IBD.[1][2]
Equillium's trajectory hinges on Phase 3 data for itolizumab in GVHD and Phase 2 readouts for BNZ-1, potentially unlocking approvals and partnerships in high-value immuno-inflammatory markets.[2] Trends like AI-driven drug discovery and cytokine engineering will accelerate its preclinical assets (e.g., BNZ-3, EQ-302), while combination therapies could broaden impact.[2] As a nimble clinical-stage player, its influence may grow through milestone-driven financing or acquisitions, solidifying its role in pioneering immune-targeted treatments for patients with limited options—echoing its founding mission to transform autoimmune care.[1][3]
Key people at Equillium, Inc..
